RU2019107667A - Спироциклические соединения - Google Patents

Спироциклические соединения Download PDF

Info

Publication number
RU2019107667A
RU2019107667A RU2019107667A RU2019107667A RU2019107667A RU 2019107667 A RU2019107667 A RU 2019107667A RU 2019107667 A RU2019107667 A RU 2019107667A RU 2019107667 A RU2019107667 A RU 2019107667A RU 2019107667 A RU2019107667 A RU 2019107667A
Authority
RU
Russia
Prior art keywords
cancer
pharmaceutically acceptable
acceptable salt
compound according
group
Prior art date
Application number
RU2019107667A
Other languages
English (en)
Russian (ru)
Other versions
RU2019107667A3 (enExample
Inventor
Питер Циньхуа ХУАН
Мехмет Кахраман
Кевин Дуэйн БАНКЕР
Original Assignee
РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС filed Critical РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС
Publication of RU2019107667A publication Critical patent/RU2019107667A/ru
Publication of RU2019107667A3 publication Critical patent/RU2019107667A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2019107667A 2016-10-05 2017-10-03 Спироциклические соединения RU2019107667A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404668P 2016-10-05 2016-10-05
US62/404,668 2016-10-05
PCT/US2017/054865 WO2018067512A1 (en) 2016-10-05 2017-10-03 Spirocyclic compounds

Publications (2)

Publication Number Publication Date
RU2019107667A true RU2019107667A (ru) 2020-11-06
RU2019107667A3 RU2019107667A3 (enExample) 2021-01-27

Family

ID=61831517

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019107667A RU2019107667A (ru) 2016-10-05 2017-10-03 Спироциклические соединения

Country Status (13)

Country Link
US (2) US10934304B2 (enExample)
EP (1) EP3523306A4 (enExample)
JP (2) JP6949952B2 (enExample)
KR (1) KR20190075931A (enExample)
CN (1) CN109890827A (enExample)
AU (1) AU2017339890A1 (enExample)
BR (1) BR112019005305A2 (enExample)
CA (1) CA3037064A1 (enExample)
IL (1) IL265752A (enExample)
MX (1) MX2019003938A (enExample)
RU (1) RU2019107667A (enExample)
TW (1) TW201817732A (enExample)
WO (1) WO2018067512A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP3277690B1 (en) 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
AU2019334264B2 (en) * 2018-09-07 2024-10-31 Merck Patent Gmbh 5-Morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) * 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
CN110922421B (zh) * 2019-12-17 2023-05-05 安徽英特美科技有限公司 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
CN122094959A (zh) * 2023-10-31 2026-05-26 C4医药公司 用于降解突变体braf的化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2897422T3 (es) * 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
ES2372976T3 (es) * 2005-12-13 2012-01-30 Schering Corporation Derivados de indazol policíclicos que son inhibidores de erk.
JP5380296B2 (ja) 2006-11-17 2014-01-08 ポリエラ コーポレイション ジイミド系半導体材料ならびにジイミド系半導体材料を調製および使用する方法
MX2009014208A (es) * 2007-06-18 2010-01-28 Schering Corp Compuestos heterociclicos y usos de los mismos como inhibidores de erk.
EP2318388A2 (en) 2008-07-23 2011-05-11 Schering Corporation Tricyclic spirocycle derivatives and methods of use thereof
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2013033059A1 (en) * 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
CN103130775B (zh) 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) * 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
US9447025B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
JP6322770B2 (ja) 2014-12-22 2018-05-09 イーライ リリー アンド カンパニー Erk阻害剤
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EP3277690B1 (en) * 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds

Also Published As

Publication number Publication date
US20210115058A1 (en) 2021-04-22
MX2019003938A (es) 2019-06-10
AU2017339890A1 (en) 2019-04-11
US20200207776A1 (en) 2020-07-02
TW201817732A (zh) 2018-05-16
CN109890827A (zh) 2019-06-14
RU2019107667A3 (enExample) 2021-01-27
JP6949952B2 (ja) 2021-10-13
EP3523306A1 (en) 2019-08-14
KR20190075931A (ko) 2019-07-01
JP2021193138A (ja) 2021-12-23
WO2018067512A8 (en) 2018-11-01
WO2018067512A1 (en) 2018-04-12
EP3523306A4 (en) 2020-05-06
US10934304B2 (en) 2021-03-02
JP2019534261A (ja) 2019-11-28
BR112019005305A2 (pt) 2019-07-02
NZ751398A (en) 2021-03-26
IL265752A (en) 2019-06-30
CA3037064A1 (en) 2018-04-12

Similar Documents

Publication Publication Date Title
JP2019534261A5 (enExample)
ES3058787T3 (en) N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4598916A1 (en) Heterocyclic inhibitors of kras g12c mutant proteins and uses thereof
JP7846132B2 (ja) Nav1.8阻害薬としてのアリール 3-オキソピペラジンカルボキサミド類及びヘテロアリール 3-オキソピペラジンカルボキサミド類
CN106103416B (zh) 作为trpm8拮抗剂的氮杂螺衍生物
KR20230024985A (ko) Nav1.8 억제제로서의 2-옥소이미다졸리딘-4-카르복스아미드
WO2022256702A1 (en) Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
RU2009142851A (ru) Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний
JP2021107414A (ja) コロニー刺激因子−1受容体(csf−1r)阻害剤
RU2018138584A (ru) Соединения-ингибиторы egfr
AU2020371295A1 (en) Pharmaceutical combination of PRMT5 inhibitors
AU2018344926A1 (en) Chemical compounds
RU2012148246A (ru) 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
RU2014117515A (ru) Макроциклические ингибиторы киназы lrrk2
JP2013541513A5 (enExample)
EA018721B1 (ru) Модуляторы сигнального пути hedgehog
RU2014130125A (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
KR20110137406A (ko) 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로[2,3-b]피리딘 및 피롤로[2,3-b]피리미딘
EA020136B1 (ru) Производные пиколинамида в качестве ингибиторов киназы
CN103539777B (zh) Pi3激酶调节剂及其使用方法和用途
JP2016531858A5 (enExample)
EP3207039B1 (en) Aldosterone synthase inhibitors
HRP20171696T1 (hr) 3,4-dihidroizokinolin-2(1h)-ilni spojevi
RU2016110483A (ru) Производные пирролопиридина или пиразолопиридина

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20220110